Course Director

Alexander D. Rae-Grant
Alexander D. Rae-Grant, MD

Clinical Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director of Resident and Student Education
Mellen Center for Multiple Sclerosis Treatment and Research
Cleveland Clinic
Cleveland, OH


Alasdair Coles, PhD

Department of Clinical Neurosciences
University of Cambridge
Cambridge, England

Devon Conway, MD, MS

Assistant Professor
Cleveland Clinic Lerner College of Medicine
Staff Neurologist
Mellen Center for Multiple Sclerosis
Neurological Institute
Cleveland Clinic
Cleveland, OH

Carrie M. Hersh, DO, MSc

Cleveland Clinic
Cleveland, OH

Le H. Hua, MD

Eric and Sheila Samson Chair for Multiple Sclerosis Research
Director, Mellen Program for Multiple Sclerosis
Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, NV

Stephen Jones, MD, PhD

Diagnostic Radiology
Cleveland Clinic
Cleveland, OH

Elias Khawam, MD

Cleveland Clinic
Cleveland, OH

Fred Lublin, MD

Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY

Don J. Mahad, MD, PhD

Centre for Clinical Brain Sciences
Anne Rowling Regenerative Neurology Clinic
Centre for Neuroregeneration
The University of Edinburgh
Edinburgh, Scotland

Marisa McGinley, MD

Mellen Center for Multiple Sclerosis Treatment and Research
Cleveland Clinic
Cleveland, OH

Daniel Ontaneda, MD, MSc

Staff Neurologist
Mellen Center for Multiple Sclerosis
Cleveland Clinic
Cleveland, OH

Mary Alissa Willis, MD

Staff Neurologist
Mellen Center for Multiple Sclerosis
Cleveland Clinic
Cleveland, OH

Dean M. Wingerchuk, MD, MSc, FRCP(C)

Mayo Clinic
Phoenix/Scottsdale, AZ

Accredited by

Cleveland Clinic Center for Continuing Education

Course Description

Learning Objectives
1. Recognize the changes in understanding of MS pathology including evidence of active immune surveillance in the spinal fluid and early cortical lesions.
2. Summarize evidence on diagnostic use of MRI using updated guidelines for MS.
3. Critically compare the efficacies, mode of action, pharmacology, and side effect profiles of recently approved disease modifying agents for MS.
4. Describe the clinical role of the newer agents in strategies for treating patients with relapsing MS.
5. Develop a risk mitigation strategy to reduce adverse effects associated with disease modifying therapies.
6. Summarize research on incidence of comorbidities associated with MS and their potential impact on MS.
7. Describe the importance of depression and cognitive impairment in patients with MS and identify strategies to address depression management in these patients.

Activity Details

Credit Types:CME
Credit Amount:1.25 Credits
Release Date:2017-Oct-30
Expiration Date:2019-Oct-30
Estimated Time for Completion:1 hour 15 minutes
Registration Required:No

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.